KraneShares CSI China Internet ETF vs Liquidia Corporation Common Stock — how do they compare? KraneShares CSI China Internet ETF trades at $24.12 (market cap $4.51B), while Liquidia Corporation Common Stock trades at $33.46 (market cap $2.40B). The key difference: KraneShares CSI China Internet ETF is the larger of the two by market cap, and Liquidia Corporation Common Stock is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 59 Days and Liquidia Corporation Common Stock for 0 Days on average.
| KWEB | LQDA | |
|---|---|---|
Market Cap | $4.51B | $2.40B |
Volume | 12,272,723 | 2,857,547 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $91.03 |
52-Week Low | $23.63 | $22.02 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $2.30B |
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.72, down 0.12% with neutral technical signals. The ETF faces mixed institutional activity amid ongoing U.S.-China trade dynamics. Recent news highlights China's economic challenges including industrial overcapacity and trade rebalancing pressures, while corporate profits showed a 26% Q2 surge according to Zacks Investment Research on September 8, 2026.
The outlook remains cautious due to geopolitical tensions and China's economic headwinds. Investment opportunity exists if U.S.-China relations improve, but risks include trade protectionism and domestic consumption weakness. Technical indicators suggest limited near-term momentum with key support at $25.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →